Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 5/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248432 | 0.87 | PIK3CA (0.49) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL248529 | 0.82 | GCK (0.40) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL248528 | 0.80 | GCK (0.46) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL30559722 | 0.71 | NPC1 (0.48) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL26977916 | 0.71 | NPC1 (0.48) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL246131 | 0.68 | CYP2C19 (0.59) | PIK3CAPIK3CBPIK3R1PDE10AMTOR | |
| SCHEMBL30659779 | 0.67 | MAPK14 (0.38) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL20657571 | 0.67 | MAPK14 (0.38) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL20242081 | 0.67 | PIK3CA (0.48) | PIK3CAPIK3CDPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL319179 | 0.67 | NNMT (0.31) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 28/4885PIK3CD 24/4885PIK3CB 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.